These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21174518)

  • 1. ALSUntangled No. 8: Low dose naltrexone for ALS.
    ALSUntangled Group
    Amyotroph Lateral Scler; 2011 Jan; 12(1):76-8. PubMed ID: 21174518
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug therapy in amyotrophic lateral sclerosis.
    Distad BJ; Meekins GD; Liou LL; Weiss MD; Carter GT; Miller RG
    Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):633-51, xi-xii. PubMed ID: 18625421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.
    Ferrante KL; Shefner J; Zhang H; Betensky R; O'Brien M; Yu H; Fantasia M; Taft J; Beal MF; Traynor B; Newhall K; Donofrio P; Caress J; Ashburn C; Freiberg B; O'Neill C; Paladenech C; Walker T; Pestronk A; Abrams B; Florence J; Renna R; Schierbecker J; Malkus B; Cudkowicz M
    Neurology; 2005 Dec; 65(11):1834-6. PubMed ID: 16344537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary on 'a novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS'.
    Shefner JM; Nigel Leigh P
    Amyotroph Lateral Scler; 2008 Aug; 9(4):254-6. PubMed ID: 18642137
    [No Abstract]   [Full Text] [Related]  

  • 5. Reversal of signs and symptoms of a B-cell lymphoma in a patient using only low-dose naltrexone.
    Berkson BM; Rubin DM; Berkson AJ
    Integr Cancer Ther; 2007 Sep; 6(3):293-6. PubMed ID: 17761642
    [No Abstract]   [Full Text] [Related]  

  • 6. [Neuroprotective therapy for amyotrophic lateral sclerosis (ALS)].
    Yanagisawa N; Shindo M
    Rinsho Shinkeigaku; 1996 Dec; 36(12):1329-30. PubMed ID: 9128396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cotreatment of amyotrophic lateral sclerosis patients].
    Iwasaki Y; Ikeda K
    Rinsho Shinkeigaku; 1999 Dec; 39(12):1253-5. PubMed ID: 10791091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC; Drory VE
    J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract]   [Full Text] [Related]  

  • 9. ALSUntangled No. 16: cannabis.
    ALSUntangled Group
    Amyotroph Lateral Scler; 2012 Jun; 13(4):400-4. PubMed ID: 22632446
    [No Abstract]   [Full Text] [Related]  

  • 10. Toward more efficient clinical trials for amyotrophic lateral sclerosis.
    Cudkowicz ME; Katz J; Moore DH; O'Neill G; Glass JD; Mitsumoto H; Appel S; Ravina B; Kieburtz K; Shoulson I; Kaufmann P; Khan J; Simpson E; Shefner J; Levin B; Cwik V; Schoenfeld D; Aggarwal S; McDermott MP; Miller RG
    Amyotroph Lateral Scler; 2010 May; 11(3):259-65. PubMed ID: 19961263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
    IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opposing effects of low and high-dose clozapine on survival of transgenic amyotrophic lateral sclerosis mice.
    Turner BJ; Rembach A; Spark R; Lopes EC; Cheema SS
    J Neurosci Res; 2003 Nov; 74(4):605-13. PubMed ID: 14598305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALSUntangled (ALSU): a scientific approach to off-label treatment options for people with ALS using tweets and twitters.
    Bedlack R; Hardiman O
    Amyotroph Lateral Scler; 2009 Jun; 10(3):129-30. PubMed ID: 19455452
    [No Abstract]   [Full Text] [Related]  

  • 14. Selecting promising ALS therapies in clinical trials.
    Cheung YK; Gordon PH; Levin B
    Neurology; 2006 Nov; 67(10):1748-51. PubMed ID: 17130405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do the benefits of currently available treatments justify early diagnosis and treatment of amyotrophic lateral sclerosis? Arguments against.
    Ludolph AC; Riepe MW
    Neurology; 1999; 53(8 Suppl 5):S46-9; discussion S55-7. PubMed ID: 10560638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective agents for clinical trials in ALS: systematic assessment.
    Burke WJ
    Neurology; 2007 Feb; 68(9):709; author reply 710. PubMed ID: 17325287
    [No Abstract]   [Full Text] [Related]  

  • 17. Autophagy, lithium, and amyotrophic lateral sclerosis.
    Pasquali L; Longone P; Isidoro C; Ruggieri S; Paparelli A; Fornai F
    Muscle Nerve; 2009 Aug; 40(2):173-94. PubMed ID: 19609902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histamine beyond its effects on allergy: Potential therapeutic benefits for the treatment of Amyotrophic Lateral Sclerosis (ALS).
    Volonté C; Apolloni S; Sabatelli M
    Pharmacol Ther; 2019 Oct; 202():120-131. PubMed ID: 31233766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis.
    Phukan J
    IDrugs; 2010 Jul; 13(7):482-96. PubMed ID: 20582873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity to self and self-maintenance: what can tumor immunology teach us about ALS and Alzheimer's disease?
    Schwartz M; Ziv Y
    Trends Pharmacol Sci; 2008 Jun; 29(6):287-93. PubMed ID: 18453002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.